MAPK Inhibitors

Novel Prevention and Treatment Approaches to Cancer
Cemile Kumas
http://faculty.smu.edu/

Vemurafenib: mechanisms of resistance and secondary skin tumors
Eric Knoche
http://hematology.wustl.edu

Extinction of auditory fear conditioning requires MAPK/ERK activation in the basolateral amygdala
Herry et al
http://people.usd.edu

A MAPK cascade in Arabidopsis innate immunity
Guillaume Tena
http://molbio.mgh.harvard.edu

Primary Pulmonary Hypertension: Recent Insights into Molecular Pathways Underlying Pathogenesis
Jonathan Alexander MD PhD
http://pulmonary.ucsf.edu

Drug Design Kinase Regulation and targeting
http://www.pharmacy.umaryland.edu

Protein kinases : Role in cell signaling & implication in human pathologies
Jayanti Tokas, Rubina Begum, Shalini Jain and Hariom Yadav
http://www.pitt.edu

Translational Control by MAPK Signaling in Long-Term Synaptic Plasticity and Memory
Raymond J. Kelleher III, Arvind Govindarajan, Hae-Yoon Jung, Hyejin Kang and Susumu Tonegawa
http://classes.biology.ucsd.edu

Chemopreventive Phytochemicals
http://www.integratedhealthcare.eu

A Road-Map to Integrated Biomarker Studies
George R. Simon, MD
http://hcc.musc.edu

Dose Escalation of Topical Curcumin
Christopher D. Lao, MD, MPH
http://www.cancer.med.umich.edu

How Organs are Stored Today
Charles Chiang, Kathy Jee, Diana Zhong
http://teams.gemstone.umd.edu

MAP Kinase family regulates the nuclear localization of Nrf2
Ngan Nguyen, Tory Hagen
http://oregonstate.edu

Signaling by Serine/Threonine Kinase Receptors
http://www.calstatela.edu

Map Kinase (Map = mitogen-activated protein kinases)
http://clasfaculty.ucdenver.edu

Triphala inhibits both in vitro and in vivo xenograft growth of pancreatic tumor cells by inducing apoptosis
Yan Shi, Ravi P Sahu and Sanjay K Srivastava
http://www.chem.wwu.edu

Cell cycle and differentiation
http://www.ap.gatech.edu

Signal Transduction
http://mcb.berkeley.edu

38 Published articles on MAPK Inhibitors
1.       de Oliveira Lopes R, Romeiro NC, de Lima CK, Louback da Silva L, de Miranda AL, Nascimento PG, Cunha FQ, Barreiro EJ, Lima LM. Docking, synthesis and pharmacological activity of novel urea-derivatives designed as p38 MAPK inhibitors. Eur J Med Chem. 2012 Aug;54.264-71. Epub 2012 May 14.
2.       Yeung YT, Bryce NS, Adams S, Braidy N, Konayagi M, McDonald KL, Teo C, Guillemin GJ, Grewal T, Munoz L. p38 MAPK inhibitors attenuate pro-inflammatory cytokine production and the invasiveness of human U251 glioblastoma cells. J Neurooncol. 2012 Aug;109(1).35-44. Epub 2012 Apr 19.
3.       Banerjee A, Koziol-White C, Panettieri R Jr. p38 MAPK inhibitors, IKK2 inhibitors, and TNFα inhibitors in COPD. Curr Opin Pharmacol. 2012 Jun;12(3).287-92. Epub 2012 Feb 24.
4.       Park WH. MAPK inhibitors and siRNAs differentially affect cell death and ROS levels in arsenic trioxide-treated human pulmonary fibroblast cells. Oncol Rep. 2012 May;27(5).1611-8. doi. 10.3892/or.2012.1661. Epub 2012 Jan 27.
5.       Chakravarty D, Santos E, Ryder M, Knauf JA, Liao XH, West BL, Bollag G, Kolesnick R, Thin TH, Rosen N, Zanzonico P, Larson SM, Refetoff S, Ghossein R, Fagin JA. Small-molecule MAPK inhibitors restore radioiodine incorporation in mouse thyroid cancers with conditional BRAF activation. J Clin Invest. 2011 Dec;121(12).4700-11. doi. 10.1172/JCI46382. Epub 2011 Nov 21.
6.       Park WH. MAPK inhibitors differentially affect gallic acid-induced human pulmonary fibroblast cell growth inhibition. Mol Med Report. 2011 Jan-Feb;4(1).193-04. doi. 10.3892/mmr.2010.361. Epub 2010 Sep 10.
7.       Bagley MC, Davis T, Dix MC, Murziani PG, Rokicki MJ, Kipling D. Microwave-assisted synthesis of a pyrazolyl ketone library for evaluation as p38  MAPK inhibitors in Werner syndrome cells. Future Med Chem. 2010 Feb;2(2).203-13.
8.       Dy G. MEK/MAPK inhibitors. J Thorac Oncol. 2010 Dec;5(12 Suppl 6).S474-5.
9.       You BR, Park WH. The enhancement of propyl gallate-induced HeLa cell death by  MAPK inhibitors is accompanied by increasing ROS levels. Mol Biol Rep. 2011 Apr;38(4).2349-58. Epub 2010 Nov 17.
10.   You BR, Park WH. MG132, a proteasome inhibitor-induced calf pulmonary arterial endothelial cell growth and death, are changed by MAPK inhibitors. Drug  Chem Toxicol. 2011 Jan;34(1).45-52. Epub 2010 Oct 18.
11.   Espelin CW, Goldsipe A, Sorger PK, Lauffenburger DA, de Graaf D, Hendriks BS. Elevated GM-CSF and IL-1beta levels compromise the ability of p38 MAPK inhibitors to modulate TNFalpha levels in the human monocytic/macrophage U937 cell line. Mol Biosyst. 2010 Oct;6(10).1956-72. Epub 2010 Jul 9.
12.   Han YH, Park WH. Pyrogallol-induced As4.1 juxtaglomerular cell death is attenuated by MAPK inhibitors via preventing GSH depletion. Arch Toxicol. 2010 Aug;84(8).631-40. Epub 2010 Feb 27.
13.   Han YH, You BR, Moon HJ, Kim SZ, Kim SH, Park WH. The effects of MAPK inhibitors on antimycin A-treated calf pulmonary arterial endothelial cells in relation to cell death, reactive oxygen species and glutathione. Mol Med Report.  2010 Jan-Feb;3(1).161-6. doi. 10.3892/mmr_00000234.
14.   Han YH, Park WH. The effects of MAPK inhibitors on a proteasome inhibitor, MG132-induced HeLa cell death in relation to reactive oxygen species and glutathione. Toxicol Lett. 2010 Feb 1;192(2).134-40. Epub 2009 Oct 23.
15.   Yong HY, Koh MS, Moon A. The p38 MAPK inhibitors for the treatment of inflammatory diseases and cancer. Expert Opin Investig Drugs. 2009 Dec;18(12).1893-905. Review.
16.   Han YH, Moon HJ, You BR, Kim SZ, Kim SH, Park WH. The effect of MAPK inhibitors on arsenic trioxide-treated Calu-6 lung cells in relation to cell death, ROS and GSH levels. Anticancer Res. 2009 Oct;29(10).3837-44.
17.   Han YH, Moon HJ, You BR, Park WH. The effects of MAPK inhibitors on pyrogallol-treated Calu-6 lung cancer cells in relation to cell growth, reactive  oxygen species and glutathione. Food Chem Toxicol. 2010 Jan;48(1).271-6. Epub 2009 Oct 13.
18.   Han YH, Park WH. The effects of MAPK inhibitors on antimycin A-treated Calu-6 lung cancer cells in relation to cell growth, reactive oxygen species, and glutathione. Mol Cell Biochem. 2010 Jan;333(1-2).211-9.
19.   Sweeney SE. The as-yet unfulfilled promise of p38 MAPK inhibitors. Nat Rev Rheumatol. 2009 Sep;5(9).475-7.
20.   Meira DD, de Almeida VH, Mororó JS, Nóbrega I, Bardella L, Silva RL, Albano RM, Ferreira CG. Combination of cetuximab with chemoradiation, trastuzumab or MAPK inhibitors. mechanisms of sensitisation of cervical cancer cells. Br J Cancer. 2009 Sep 1;101(5).782-91. Epub 2009 Aug 4.
21.   Kirkwood KL, Rossa C Jr. The potential of p38 MAPK inhibitors to modulate periodontal infections. Curr Drug Metab. 2009 Jan;10(1).55-67. Review.
22.   Gelmedin V, Caballero-Gamiz R, Brehm K. Characterization and inhibition of a  p38-like mitogen-activated protein kinase (MAPK) from Echinococcus multilocularis. antiparasitic activities of p38 MAPK inhibitors. Biochem Pharmacol. 2008 Oct 30;76(9).1068-81. Epub 2008 Aug 22.
23.   Muniyappa H, Das KC. Activation of c-Jun N-terminal kinase (JNK) by widely used specific p38 MAPK inhibitors SB202190 and SB203580. a MLK-3-MKK7-dependent mechanism. Cell Signal. 2008 Apr;20(4).675-83. Epub 2007 Dec 8.
24.   Davis T, Bagley MC, Dix MC, Murziani PG, Rokicki MJ, Widdowson CS, Zayed JM,  Bachler MA, Kipling D. Synthesis and in vivo activity of MK2 and MK2 substrate-selective p38alpha(MAPK) inhibitors in Werner syndrome cells. Bioorg Med Chem Lett. 2007 Dec 15;17(24).6832-5. Epub 2007 Oct 17.
25.   Clark JE, Sarafraz N, Marber MS. Potential of p38-MAPK inhibitors in the treatment of ischaemic heart disease. Pharmacol Ther. 2007 Nov;116(2).192-206. Epub 2007 Jul 24. Review.
26.   Wu SJ, Ng LT. MAPK inhibitors and pifithrin-alpha block cinnamaldehyde-induced apoptosis in human PLC/PRF/5 cells. Food Chem Toxicol. 2007 Dec;45(12).2446-53. Epub 2007 Jun 27.
27.   Andjelkov N, Elvenes J, Knutsen G, Johansen O. Beta-endorphin regulation of MAPKs in cultured human articular chondrocytes. MAPK inhibitors prevent the increase of IL-1 beta protein levels during beta-endorphin stimulation. Cell Commun Adhes. 2007 Jan-Feb;14(1).1-8.
28.   Nerurkar SS, Olzinski AR, Frazier KS, Mirabile RC, O'Brien SP, Jing J, Rajagopalan D, Yue TL, Willette RN. P38 MAPK inhibitors suppress biomarkers of hypertension end-organ damage, osteopontin and plasminogen activator inhibitor-1. Biomarkers. 2007 Jan-Feb;12(1).87-112.
29.   Michel AD, Thompson KM, Simon J, Boyfield I, Fonfria E, Humphrey PP. Species  and response dependent differences in the effects of MAPK inhibitors on P2X(7) receptor function. Br J Pharmacol. 2006 Dec;149(7).948-57. Epub 2006 Oct 9.
30.   Romeiro NC, Albuquerque MG, de Alencastro RB, Ravi M, Hopfinger AJ. Construction of 4D-QSAR models for use in the design of novel p38-MAPK inhibitors. J Comput Aided Mol Des. 2005 Jun;19(6).385-400.
31.   Kuldo JM, Westra J, Asgeirsdóttir SA, Kok RJ, Oosterhuis K, Rots MG, Schouten JP, Limburg PC, Molema G. Differential effects of NF-{kappa}B and p38 MAPK inhibitors and combinations thereof on TNF-{alpha}- and IL-1{beta}-induced proinflammatory status of endothelial cells in vitro. Am J Physiol Cell Physiol.  2005 Nov;289(5).C1229-39. Epub 2005 Jun 22.
32.   Moroi Y, Yu B, Urabe K, Koga T, Nakahara T, Dainichi T, Uchi H, Furue M. Effects of MAPK inhibitors on CCR4-mediated chemotaxis against thymus and activation-regulated chemokine (TARC/CCL17). J Dermatol Sci. 2004 Dec;36(3).186-8.
33.   Ju H, Behm DJ, Nerurkar S, Eybye ME, Haimbach RE, Olzinski AR, Douglas SA, Willette RN. p38 MAPK inhibitors ameliorate target organ damage in hypertension.  Part 1. p38 MAPK-dependent endothelial dysfunction and hypertension. J Pharmacol  Exp Ther. 2003 Dec;307(3).932-8. Epub 2003 Oct 15.
34.   Lenhard SC, Nerurkar SS, Schaeffer TR, Mirabile RC, Boyce RW, Adams DF, Jucker BM, Willette RN. p38 MAPK inhibitors ameliorate target organ damage in hypertension. Part 2. Improved renal function as assessed by dynamic contrast-enhanced magnetic resonance imaging. J Pharmacol Exp Ther. 2003 Dec;307(3).939-46. Epub 2003 Oct 15.
35.   Huang M, Wang Y, Collins M, Gu JJ, Mitchell BS, Graves LM. Inhibition of nucleoside transport by p38 MAPK inhibitors. J Biol Chem. 2002 Aug 9;277(32).28364-7. Epub 2002 Jun 20.
36.   Flamigni F, Facchini A, Giordano E, Tantini B, Stefanelli C. Signaling pathways leading to the induction of ornithine decarboxylase. opposite effects of p44/42 mitogen-activated protein kinase (MAPK) and p38 MAPK inhibitors. Biochem Pharmacol. 2001 Jan 1;61(1).25-32.
37.   Zubkov AY, Tibbs RE, Aoki K, Zhang JH. Prevention of vasospasm in penetrating arteries with MAPK inhibitors in dog double-hemorrhage model. Surg Neurol. 2000 Sep;54(3).221-7; discussion 227-8.
38.   Rutault K, Hazzalin CA, Mahadevan LC. Combinations of ERK and p38 MAPK inhibitors ablate tumor necrosis factor-alpha (TNF-alpha ) mRNA induction. Evidence for selective destabilization of TNF-alpha transcripts. J Biol Chem. 2001 Mar 2;276(9).6666-74. Epub 2000 Nov 13.